Melanotan II
Research OnlyAlso known as: MT-II, MT-2
A non-selective melanocortin receptor agonist known for tanning effects. Not approved by any regulatory agency; associated with significant safety concerns including melanoma risk and systemic toxicity.
Research Statistics
Non-selective melanocortin agonist with some human data; MC1R/MC4R activation mechanism is understood via FDA-approved bremelanotide (PT-141), but MT-II development halted due to safety concerns.
Research Dossier
Overview
What is Melanotan II and what does the research say?
Mechanism of Action
Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that binds non-selectively to melanocortin receptors MC1R, MC3R, MC4R, and MC5R. It was developed at the University of Arizona in the 1980s as a potential sunless tanning agent but was never approved due to safety concerns.
How It Works (Simplified)
Melanotan II acts as a “multi-target activator” affecting several body systems simultaneously:
Activates melanocytes to produce melanin pigment, causing skin darkening without UV exposure - bypassing the natural DNA-damage trigger.
Crosses blood-brain barrier to activate hypothalamic MC4R receptors, triggering dopamine release and spontaneous sexual arousal.
MC4R activation in hypothalamic appetite centers reduces hunger signaling, causing decreased food intake.
Melanocortin receptor activation causes pressor effects, raising blood pressure - a key safety concern noted in trials.
Scientific Pathways
MC1R Tanning Pathway (Melanogenesis)
MT-II → MC1R on melanocytes → Gs protein → Adenylyl cyclase → cAMP
↓
PKA → MITF activation
↓
Tyrosinase transcription
↓
Eumelanin synthesis (tanning)MC4R Sexual Function Pathway (CNS)
MT-II → Crosses BBB → MC4R in mPOA → Dopamine release → Sexual arousal
↓
Erection without stimulationKey Research: Dorr RT et al. (Arizona, 1996) demonstrated tanning without UV exposure in the first human trial. PMID:8637402
Important Limitations
- Non-selective binding causes multiple unpredictable systemic effects
- Bypasses natural UV-triggered tanning surveillance mechanisms
- Associated with melanoma development in multiple case reports
- Never completed Phase 3 clinical trials
- Not approved by FDA, TGA, EMA, or any regulatory agency
- PT-141 (bremelanotide) was developed as a more selective alternative for sexual function
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Initial administration may produce acute side effects including nausea, facial flushing, fatigue, and spontaneous erections. These effects are commonly reported from first dose and typically diminish with continued use.
Early tanning effects may become visible, particularly with UV exposure. Freckles and existing moles may begin to darken. Appetite suppression and sexual effects often manifest during this period.
Progressive skin darkening continues. Users report noticeable tan development. Mole changes may become more apparent. Side effects typically stabilize or diminish.
Maximum tanning effect generally reached by 4-8 weeks. Some users transition to maintenance dosing. Long-term effects on moles and melanocyte activity remain concerning. No long-term safety data available.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Melanotan II product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Melanotan II with other peptides. Based on published research and mechanistic considerations.
BPC-157
CautionBPC-157 has pro-angiogenic effects. Melanotan II stimulates melanocyte activity. Theoretical concern about combined effects on moles/nevi. No interaction studies available.
Semaglutide
CautionBoth can cause nausea. Melanotan II commonly causes GI effects. Monitor for additive adverse events.
Thymosin-Alpha-1
CautionBoth modulate immune function. Melanotan II's melanocortin effects may interact with immune signaling. Exercise caution.
GHK-Cu
CautionBoth may affect skin/pigmentation. GHK-Cu promotes wound healing while MT-II stimulates melanogenesis. Unknown if combined effects are safe for moles/nevi.
PT-141
AvoidPT-141 (bremelanotide) is derived from Melanotan II with more selective melanocortin receptor activity. Combining provides redundant stimulation with increased risk of adverse events.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Melanotan II
Melanotan II Calculators
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.